Pacific Edge Limited (NZX/ ASX: PEB), a cancer diagnostics company based in Dunedin, New Zealand, has reported a record number of 9,706 tests processed in its laboratories in the first quarter of the 2024 financial year (Q1 24), a 38% increase on the same quarter of the prior year (Q1 23).
US test volumes rose 10% to 8,627 in Q1 24, while Asia Pacific volumes increased by 2% to 1,079.
The company has also gained a stay on the 'Genetic Testing for Oncology' Local Coverage Determination (LCD, L39365), which has the potential to end Medicare coverage of Cxbladder in the US.
See more
